ACM
KRTX

Atika Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Atika Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$6.33M – 117
2023
Q4 		$6.33M Sell
20,000
-23,500
-54% -$4.57M 0.85% 49
2023
Q3 		$7.36M Sell
43,500
-21,500
-33% -$4.04M 0.97% 43
2023
Q2 		$14.1M Buy
65,000
+22,725
+54% +$4.87M 1.41% 23
2023
Q1 		$7.68M Sell
42,275
-6,806
-14% -$1.3M 1.13% 33
2022
Q4 		$9.64M Sell
49,081
-41,919
-46% -$8.99M 1.39% 24
2022
Q3 		$20.5M Buy
91,000
+38,000
+72% +$7.69M 1.74% 16
2022
Q2 		$6.71M Sell
53,000
-19,000
-26% -$2.18M 0.75% 44
2022
Q1 		$9.13M Sell
72,000
-3,000
-4% -$338K 0.77% 45
2021
Q4 		$9.82M Buy
+75,000
New +$9.69M 0.69% 58
2021
Q2 		– Sell
-11,000
Closed -$1.32M – 119
2021
Q1 		$1.32M Sell
11,000
-53,000
-83% -$6M 0.11% 88
2020
Q4 		$6.5M Sell
64,000
-9,500
-13% -$880K 0.51% 73
2020
Q3 		$5.68M Sell
73,500
-1,500
-2% -$128K 0.47% 67
2020
Q2 		$8.36M Sell
75,000
-15,000
-17% -$1.3M 1.08% 35
2020
Q1 		$6.48M Buy
90,000
+17,000
+23% +$1.45M 1.24% 26
2019
Q4 		$5.5M Buy
+73,000
New +$3.2M 1.06% 47

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Atika Capital Management's KRTX Position: Q1 2024 in Review

Atika Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 20,000 shares — an estimated $6.33M sold.

Atika Capital Management first reported a position in KRTX in Q4 2019 and held it in 15 quarters. The position peaked at $20.5M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Atika Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Atika Capital Management sold 20,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.33M.
  • Atika Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 15 quarters.
  • Atika Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $20.5M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Atika Capital Management's 13F filing for Q1 2024, filed 14 May 2024.